Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Tosufloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT4 known ✓ | P35916 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.82 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | HPGD | P15428 | 1/20 | 0.68 |
| ▸ | XBP1 | P17861 | 1/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.68 |
| ▸ | RELA | Q04206 | 1/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.68 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.64 |
| ▸ | GSK3B | P49841 | 1/20 | 0.64 |
| ▸ | RARB | P10826 | 1/20 | 0.64 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.64 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.64 |
| ▸ | DPP4 | P27487 | 3/20 | 0.46 |
| ▸ | TOP2A | P11388 | 12/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tosufloxacin SCHEMBL29489393 | 0.99 | KMT2A (0.81) | KMT2AKDM4EALDH1A1LMNAPOLB | |
| Tosufloxacin SCHEMBL9478630 | 0.99 | KMT2A (0.81) | KMT2AKDM4EALDH1A1LMNAPOLB | |
| Tosufloxacin SCHEMBL27512285 | 0.92 | KMT2A (0.90) | KMT2AKDM4EALDH1A1LMNAPOLB | |
| Tosufloxacin SCHEMBL9691051 | 0.92 | KMT2A (0.93) | KMT2AKDM4EALDH1A1LMNAPOLB | |
| Tosufloxacin SCHEMBL29383684 | 0.91 | KMT2A (1.00) | KMT2AKDM4EALDH1A1LMNAPOLB | |
| Tosufloxacin SCHEMBL9323984 | 0.91 | KMT2A (1.00) | KMT2AKDM4EALDH1A1LMNAPOLB | |
| Tosufloxacin SCHEMBL34354 | 0.91 | KMT2A (1.00) | KMT2AKDM4EALDH1A1LMNAPOLB | |
| Tosufloxacin SCHEMBL34355 | 0.91 | KMT2A (1.00) | KMT2AKDM4EALDH1A1LMNAPOLB | |
| SCHEMBL7005273 | 0.90 | KMT2A (0.66) | KMT2AKDM4EALDH1A1LMNAPOLB | |
| Tosufloxacin SCHEMBL3754459 | 0.90 | KMT2A (0.98) | KMT2AKDM4EALDH1A1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 273 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122056891-A | Eye drop containing tosufloxacin tosylate and dexamethasone and preparation method thereof | 山东序列生物科技有限公司 | 2026-05-19 | — | — | CN | claimed |
| CN-119280144-A | Tosufloxacin tosylate antibacterial external preparation and preparation method thereof | 山东序列生物科技有限公司 | 2025-01-10 | — | — | CN | claimed |
| CN-118878838-A | Preparation method and application of metal organic framework material for adsorbing quinolone medicines | 新疆畜牧科学院畜牧业质量标准研究所（新疆维吾尔自治区种羊与羊毛羊绒质量安全监督检验中心） | 2024-11-01 | — | — | CN | claimed |
| CN-115974746-B | Synthesis method of tosufloxacin tosylate intermediate | 天地恒一制药股份有限公司 | 2024-10-01 | — | — | CN | claimed |
| CN-118121709-A | Ophthalmic pharmaceutical composition, and preparation method and application thereof | 山东序列生物科技有限公司 | 2024-06-04 | — | — | CN | claimed |
| CN-117562858-A | Tosulfloxacin tosylate eye drops and preparation method thereof | 山东序列生物科技有限公司 | 2024-02-20 | — | — | CN | claimed |
| CN-115974746-A | Synthetic method of tosufloxacin tosylate intermediate | 天地恒一制药股份有限公司 | 2023-04-18 | — | — | CN | claimed |
| EP-4057813-A1 | COMPOSITIONS AND METHODS FOR TREATING HUANGLONGBING DISEASE IN CITRUS | New Life Crop Sciences LLC (US) | 2022-09-21 | — | — | EP | claimed |
| CN-114980736-A | Compositions and methods for treating citrus greening disease | 新生命作物科学有限责任公司 | 2022-08-30 | — | — | CN | claimed |
| CN-114569551-A | Atropine eye drops and preparation method thereof | 杭州赫尔斯科技有限公司 | 2022-06-03 | — | — | CN | claimed |
| CN-114369092-A | Tosufloxacin tosylate and preparation method thereof | 赤峰万泽药业股份有限公司 | 2022-04-19 | — | — | CN | claimed |
| US-20210144998-A1 | COMPOSITIONS AND METHODS FOR TREATING HUANGLONGBING DISEASE IN CITRUS | NEW LIFE CROP SCIENCES LLC | 2021-05-20 | — | — | US | claimed |
| WO-2021097410-A1 | COMPOSITIONS AND METHODS FOR TREATING HUANGLONGBING DISEASE IN CITRUS | NEW LIFE CROP SCIENCES LLC (US) | 2021-05-20 | — | — | WO | claimed |
| CN-107519145-B | Tosufloxacin tosylate effervescent tablet for children and preparation method thereof | 正大制药（青岛）有限公司 | 2021-04-30 | — | — | CN | claimed |
| CN-107375211-B | Children sublingual spray of tosufloxacin tosylate and preparation method thereof | 正大制药（青岛）有限公司 | 2021-02-26 | — | — | CN | claimed |
| CN-108096584-B | By using supercritical CO2Tosufloxacin tosylate/cyclodextrin inclusion compound prepared by technology, preparation method and oral preparation thereof | 内蒙古工业大学 | 2021-02-05 | — | — | CN | claimed |
| CN-106176646-B | Tosufloxacin tosylate dispersible tablets and preparation method thereof | 珠海同源药业有限公司 | 2020-08-11 | — | — | CN | claimed |
| CN-106310286-B | Tosufloxacin tosylate composition | 珠海同源药业有限公司 | 2020-04-10 | — | — | CN | claimed |
| US-20050089577-A1 | Liquid matrix undergoing phase transfer in vivo and liquid oral preparations | MEDRX CO., LTD. (JP) | 2005-04-28 | — | — | US | claimed |
| EP-1488812-A1 | LIQUID MATRIX UNDERGOING PHASE TRANSFER IN VIVO AND LIQUID ORAL PREPARATIONS | Medrx Co. Ltd. (JP) | 2004-12-22 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210144998-A1 | COMPOSITIONS AND METHODS FOR TREATING HUANGLONGBING DISEASE IN CITRUS | PNPO, G6PD, AGXT | FLT4 753/4885KMT2A 3670/4885KDM4E 2866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.